|
1
|
Gupta P, Tewari M and Shukla HS:
Gastrointestinal stromal tumors. Surg Oncol. 17:129–138. 2008.
View Article : Google Scholar
|
|
2
|
Katz SC and DeMatteo RP: Gastrointestinal
stromal tumors and leiomyosarcomas. J Surg Oncol. 97:350–359. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Delahaye NF, Rusakiewicz S, Martins I, et
al: Alternatively spliced NKp30 isoforms affect the prognosis of
gastrointestinal stromal tumors. Nat Med. 17:700–707. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kikuta K, Kubota D, Saito T, et al:
Clinical proteomics identified ATP-dependent RNA helicase DDX39 as
a novel biomarker to predict poor prognosis of patients with
gastrointestinal stromal tumor. J Proteomics. 75:1089–1098. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
González-Cámpora R, Delgado MD, Amate AH,
et al: Old and new immunohistochemical markers for the diagnosis of
gastrointestinal stromal tumors. Anal Quant Cytol Histol. 33:1–11.
2011.PubMed/NCBI
|
|
6
|
Zong L, Chen P and Xu Y: Correlation
between P53 expression and malignant risk of gastrointestinal
stromal tumors: evidence from 9 studies. Eur J Surg Oncol.
38:189–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Oliveira AT, Pinheiro C, Longatto-Filho
A, et al: Co-expression of monocarboxylate transporter 1 (MCT1) and
its chaperone (CD147) is associated with low survival in patients
with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr.
44:171–178. 2012.PubMed/NCBI
|
|
8
|
Yin AH, Miraglia S, Zanjani ED, et al:
AC133, a novel marker for human hematopoietic stem and progenitor
cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
|
|
9
|
Shmelkov SV, St Clair R, Lyden D and Rafii
S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 37:715–719.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen YC, Hsu HS, Chen YW, et al: Oct-4
expression maintained cancer stem-like properties in lung
cancer-derived CD133-positive cells. PLoS ONE. 3:e26372008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsumoto K, Arao T, Tanaka K, et al: mTOR
signal and hypoxiainducible factor-1 alpha regulate CD133
expression in cancer cells. Cancer Res. 69:7160–7164. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qin K, Jiang X, Zou Y, et al: Study on the
proliferation and drug resistance of human brain tumor stem like
cells. Cell Mol Neurobiol. 30:955–960. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moriyama T, Ohuchida K, Mizumoto K, et al:
Enhanced cell migration and invasion of CD133+ pancreatic cancer
cells cocultured with pancreatic stromal cells. Cancer.
116:3357–3368. 2010.
|
|
14
|
Ding W, You H, Dang H, et al:
Epithelial-to-mesenchymal transition of murine liver tumor cells
promotes invasion. Hepatology. 52:945–953. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arne G, Kristiansson E, Nerman O, et al:
Expression profiling of GIST: CD133 is associated with KIT exon 11
mutations, gastric location and poor prognosis. Int J Cancer.
129:1149–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wong NA, Young R, Malcomson RD, et al:
Prognostic indicators for gastrointestinal stromal tumours: a
clinicopathological and immunohistochemical study of 108 resected
cases of the stomach. Histopathology. 43:118–126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakamura N, Yamamoto H, Yao T, et al:
Prognostic significance of expressions of cell-cycle regulatory
proteins in gastrointestinal stromal tumor and the relevance of the
risk grade. Hum Pathol. 36:828–837. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miettinen M and Lasota J: KIT (CD117): a
review on expression in normal and neoplastic tissues, and
mutations and their clinicopathologic correlation. Appl
Immunohistochem Mol Morphol. 13:205–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elias J: Immunhistopathology: A Practical
Approach to Diagnosis. ASCP Press; Chicago, IL: 1990
|
|
20
|
Taylor CR: Immunoperoxidase techniques:
practical and theoretical aspects. Arch Pathol Lab Med.
102:113–121. 1978.PubMed/NCBI
|
|
21
|
Joensuu H: Risk stratification of patients
diagnosed with gastrointestinal stromal tumor. Hum Pathol.
39:1411–1419. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dematteo RP: Personalized therapy:
prognostic factors in gastrointestinal stromal tumor (GIST). J
Gastrointest Surg. 16:1645–1647. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McCarter MD, Antonescu CR, Ballman KV, et
al; American College of Surgeons Oncology Group (ACOSOG) Intergroup
Adjuvant Gist Study Team. Microscopically positive margins for
primary gastrointestinal stromal tumors: analysis of risk factors
and tumor recurrence. J Am Coll Surg. 215:53–59. 2012. View Article : Google Scholar
|
|
24
|
Attili SV, Ananda B, Mandapal T, et al:
Factors influencing progression-free survival in gastrointestinal
stromal tumors with special reference to pathologic features,
cytogenetics, and radiologic response. Gastrointest Cancer Res.
4:173–177. 2011.
|
|
25
|
Weigmann A, Corbeil D, Hellwig A and
Huttner WB: Prominin, a novel microvilli-specific polytopic
membrane protein of the apical surface of epithelial cells, is
targeted to plasmalemmal protrusions of nonepithelial cells. Proc
Natl Acad Sci USA. 94:12425–12430. 1997. View Article : Google Scholar
|
|
26
|
Singh SK, Hawkins C, Clarke ID, et al:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chew MF, Teoh KH and Cheah PL: CD133 marks
for colorectal adenocarcinoma. Malays J Pathol. 34:25–28.
2012.PubMed/NCBI
|
|
28
|
Reggiani Bonetti L, Migaldi M, Caredda E,
et al: Increased expression of CD133 is a strong predictor of poor
outcome in stage I colorectal cancer patients. Scand J
Gastroenterol. 47:1211–1217. 2012.PubMed/NCBI
|
|
29
|
Hutchins JR, Toyoda Y, Hegemann B, et al:
Systematic analysis of human protein complexes identifies
chromosome segregation proteins. Science. 328:593–599. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Artigiani Neto R, Logullo AF, Stávale JN
and Lourenço LG: Ki-67 expression score correlates to survival rate
in gastrointestinal stromal tumors (GIST). Acta Cir Bras.
27:315–321. 2012.PubMed/NCBI
|
|
31
|
Lamba G, Ambrale S, Lee B, et al: Recent
advances and novel agents for gastrointestinal stromal tumor
(GIST). J Hematol Oncol. 5:212012. View Article : Google Scholar : PubMed/NCBI
|
